Literature DB >> 23348290

Regression modeling to inform cell incorporation into therapies for craniosynostosis.

James Cray1, Gregory M Cooper.   

Abstract

Designing an appropriate tissue engineering solution for craniosynostosis (CS) necessitates determination of whether CS-derived cells differ from normal (wild-type, WT) cells and what assays are appropriate to test for differences. Traditional methodologies to statistically compare cellular behavior may not accurately reflect biologically relevant differences because they poorly address variation. Here, logistic regression was used to determine which assays could identify a biological difference between WT and CS progenitor cells. Quantitative alkaline phosphatase and MTS proliferation assays were performed on adipose, muscle, and bone marrow-derived cells from WT and CS rabbits. Data were stratified by assay, cell type, and days in culture. Coefficients of variation were calculated and assay results coded as predictive variables. Phenotype (WT or CS) was coded as the dependent variable. Sensitivity-specificity curves, classification tables, and receiver operating characteristic curves were plotted for discriminating models. Two data sets were utilized for subsequent analyses; one was used to develop the logistic regression models for prediction, and the other independent data set was used to determine the ability to predict group membership based on the predictive equation. The resulting coefficients of variation were high for all differentiation measures. Upon model implementation, bone marrow assays were observed to result in 72%-100% predictability for phenotype. We found predictive differences in our muscle-derived and bone marrow-derived cells suggesting biologically relevant differences. This data analysis methodology could help identify homogenous cells that do not differ between pathologic and normal individuals or cells that differ in their osteogenic potential, depending on the type of cell-based therapy being developed.

Entities:  

Mesh:

Year:  2013        PMID: 23348290      PMCID: PMC3563160          DOI: 10.1097/SCS.0b013e31826cfe09

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  40 in total

Review 1.  Concerns and hopes for stem cell therapy in cardiology: focus on endothelial progenitor cells.

Authors:  R Ferrari; C A Beltrami; L Tavazzi
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-09-01

Review 2.  Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system.

Authors:  Judith A Shizuru; Robert S Negrin; Irving L Weissman
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

3.  Human adipose tissue is a source of multipotent stem cells.

Authors:  Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

4.  High variability in rabbit bone marrow-derived mesenchymal cell preparations.

Authors:  L A Solchaga; B Johnstone; J U Yoo; V M Goldberg; A I Caplan
Journal:  Cell Transplant       Date:  1999 Sep-Oct       Impact factor: 4.064

Review 5.  Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation.

Authors:  C Clar; E Cummins; L McIntyre; S Thomas; J Lamb; L Bain; P Jobanputra; N Waugh
Journal:  Health Technol Assess       Date:  2005-12       Impact factor: 4.014

Review 6.  Stem cell technology for neurodegenerative diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Junguk Hur; Eva L Feldman
Journal:  Ann Neurol       Date:  2011-09       Impact factor: 10.422

7.  Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.

Authors:  Roel J W van Kampen; Carmen Canals; Harry C Schouten; Arnon Nagler; Kirsty J Thomson; Jean-Paul Vernant; Agnes Buzyn; Marc A Boogaerts; Jian-Jian Luan; Sébastien Maury; Noel J Milpied; Jean-Pierre Jouet; Gert J Ossenkoppele; Anna Sureda
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

Review 8.  Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.

Authors:  G Hütter; J A Zaia
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

Review 9.  Stem cell-based approaches to treating HIV infection.

Authors:  Scott G Kitchen; Jerome A Zack
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

10.  Visual field results and optic disc morphology in patients treated with allogeneic stem-cell transplantation in childhood.

Authors:  Alba Lucia Törnquist; Monica Olsson; Lene Martin; Jacek Winiarski; Kristina Teär Fahnehjelm
Journal:  Acta Ophthalmol       Date:  2011-02       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.